Streetbeat News

Regulatory

CRNX

Crinetics Pharmaceuticals is set to present its advancements in neuroendocrine tumor treatments at the NANETS Annual Meeting. The company will debut its novel nonpeptide drug conjugate platform, highlighting the preclinical profile of its lead candidate, CRN09682, which targets SST2-expressing tumors and is expected to submit an IND by early 2025.

Portfolio Pulse from

November 12, 2024 | 9:30 pm

BHVN

Biohaven Ltd. reported its Q3 2024 financial results, highlighting $642 million in cash and securities. The company achieved positive trial results for troriluzole in spinocerebellar ataxia, with plans for an NDA re-submission. Biohaven is advancing multiple drug programs, including taldefgrobep alfa for spinal muscular atrophy and obesity, and BHV-2100 for migraine and neuropathic pain.

Portfolio Pulse from

November 12, 2024 | 9:15 pm

QTRX

Quanterix Corporation announced preliminary financial results for Q3 2024 and reaffirmed its full-year guidance. The company will restate certain prior period financial statements due to non-cash errors.

Portfolio Pulse from

November 12, 2024 | 9:15 pm

CLYM

Climb Bio announced its Q3 2024 financial results and business updates, including the appointment of Douglas Williams, Ph.D. as Chair of the Board, FDA clearance for an IND for systemic lupus erythematosus, and the addition of Gary Hao, Ph.D. to the management team.

Portfolio Pulse from

November 12, 2024 | 9:15 pm

HRB

H&R Block has agreed to a $7 million settlement with the FTC over allegations of deceptive claims regarding 'free' tax filing services. The settlement includes changes to some of H&R Block's business practices.

Portfolio Pulse from

November 12, 2024 | 9:15 pm

DERM

Journey Medical Corporation announced its Q3 2024 financial results and highlighted the FDA approval of Emrosi™ for rosacea treatment, with a launch expected in early 2025.

Portfolio Pulse from

November 12, 2024 | 9:15 pm

ATAI

RFK Jr's potential role in health policy under President-elect Trump could boost psychedelic drug development, as he supports this drug class. Analysts at Jefferies highlight his positive inclination towards psychedelics, which have reportedly aided his family and friends.

Portfolio Pulse from

November 12, 2024 | 9:00 pm

AZN

Levi & Korsinsky has initiated an investigation into AstraZeneca PLC (NASDAQ:AZN) for potential violations of federal securities laws. This follows reports from Chinese media about a fraud investigation involving AstraZeneca and several Chinese government agencies, implicating numerous senior executives.

Portfolio Pulse from

November 12, 2024 | 9:00 pm

CRUS

Cirrus SR Series G7 and G2+ Vision Jet have received Transport Canada Civil Aviation certification, confirming their compliance with Canadian aviation safety and performance standards.

Portfolio Pulse from

November 12, 2024 | 8:45 pm

AAL

JBLU

SAVE

The FAA has banned U.S.-Haiti flights for 30 days following an incident where a Spirit Airlines flight was struck by gunfire. Spirit, American, and JetBlue have suspended their flights to Haiti.

Portfolio Pulse from

November 12, 2024 | 8:30 pm